Taysha Gene Therapies, Inc. announced that it has entered into agreement for a private placement of common shares share for proceeds of $80,000,000 on October 21, 2022. The transaction will include participation from Astellas Pharma Inc. for 15% stake and Audentes Therapeutics, Inc. for 7,266,342 shares for proceeds of $30,009,992.46. The securities are subject to Regulation D.